Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin vs Caspofungin in Candidemia and Invasive Candidiasis
NCT02734862Phase 2Completed
- Sponsor
- Cidara Therapeutics
- Start
- Jul 2016
- Primary completion
- Jun 2019
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of rezafungin in candidemia, invasive candidiasis, sponsored by Cidara Therapeutics. Started Jul 2016; status: completed.
02
Drugs
rezafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT02734862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734862.